Top

Published in:

01-03-2014 | Original Article

Serum tenascin-C level is associated with coronary plaque rupture in patients with acute coronary syndrome

Authors: Nobuo Sakamoto, Yasuto Hoshino, Tomofumi Misaka, Hiroyuki Mizukami, Satoshi Suzuki, Koichi Sugimoto, Takayoshi Yamaki, Hiroyuki Kunii, Kazuhiko Nakazato, Hitoshi Suzuki, Shu-ichi Saitoh, Yasuchika Takeishi

Published in: Heart and Vessels | Issue 2/2014

Abstract

Tenascin-C, a large oligometric glycoprotein of the extracellular matrix, increases the expression of matrix metalloproteinases that lead to plaque instability and rupture, resulting in acute coronary syndrome (ACS). We hypothesized that a high serum tenascin-C level is associated with plaque rupture in patients with ACS. Fifty-two consecutive ACS patients who underwent emergency percutaneous coronary intervention (PCI) and, as a control, 66 consecutive patients with stable angina pectoris (SAP) were enrolled in this study. Blood samples were obtained from the ascending aorta just prior to the PCI procedures. After coronary guide-wire crossing, intravascular ultrasonography (IVUS) was performed for assessment of plaque characterization. Based on the IVUS findings, ACS patients were assigned to two groups according to whether there was ruptured plaque (ruptured ACS group) or not (nonruptured ACS group). There were 23 patients in the ruptured group and 29 patients in the nonruptured group. Clinical characteristics and IVUS measurements did not differ between the two groups. Tenascin-C levels were significantly higher in the ruptured ACS group than in the SAP group, whereas there was no significant difference between the nonruptured ACS and SAP groups. Importantly, in the ruptured ACS group, tenascin-C levels were significantly higher than in the nonruptured ACS group (71.9 ± 34.9 vs 50.5 ± 20.5 ng/ml, P < 0.005). Our data demonstrate that tenascin-C level is associated with pathologic conditions in ACS, especially the presence of ruptured plaque.

Midwood KS, Hussenet T, Langlois B, Orend G (2011) Advances in tenascin-C biology. Cell Mol Life Sci 68:3175–3199PubMedCentralPubMedCrossRef

Midwood KS, Orend G (2009) The role of tenascin-C in tissue injury and tumorigenesis. J Cell Commun Signal 3:287–310PubMedCentralPubMedCrossRef

Hedin U, Holm J, Hansson GK (1991) Induction of tenascin in rat arterial injury. Relationship to altered smooth muscle cell phenotype. Am J Pathol 139:649–656PubMedCentralPubMed

LaFleur DW, Chiang J, Fagin JA, Schwartz SM, Shah PK, Wallner K, Forrester JS, Sharifi BG (1997) Aortic smooth muscle cells interact with tenascin-C through its fibrinogen-like domain. J Biol Chem 272:32798–32803PubMedCrossRef

Maseruka H, Ridgway A, Tullo A, Bonshek R (2000) Developmental changes in patterns of expression of tenascin-C variants in the human cornea. Invest Ophthalmol Vis Sci 41:4101–4107PubMed

Cowan KN, Jones PL, Rabinovitch M (1999) Regression of hypertrophied rat pulmonary arteries in organ culture is associated with suppression of proteolytic activity, inhibition of tenascin-C, and smooth muscle cell apoptosis. Circ Res 84:1223–1233PubMedCrossRef

Mackie EJ (1997) Molecules in focus: tenascin-C. Int J Biochem Cell Biol 29:1133–1137PubMedCrossRef

Wallner K, Li C, Shah PK, Fishbein MC, Forrester JS, Kaul S, Sharifi BG (1999) Tenascin-C is expressed in macrophage-rich human coronary atherosclerotic plaque. Circulation 99:1284–1289PubMedCrossRef

Imanaka-Yoshida K, Hiroe M, Nishikawa T, Ishiyama S, Shimojo T, Ohta Y, Sakakura T, Yoshida T (2001) Tenascin-C modulates adhesion of cardiomyocytes to extracellular matrix during tissue remodeling after myocardial infarction. Lab Invest 81:1015–1024PubMedCrossRef

10.

Imanaka-Yoshida K, Hiroe M, Yasutomi Y, Toyozaki T, Tsuchiya T, Noda N, Maki T, Nishikawa T, Sakakura T, Yoshida T (2002) Tenascin-C is a useful marker for disease activity in myocarditis. J Pathol 197:388–394PubMedCrossRef

11.

Terasaki F, Okamoto H, Onishi K, Sato A, Shimomura H, Tsukada B, Imanaka-Yoshida K, Hiroe M, Yoshida T, Kitaura Y, Kitabatake A, Study Group for Intractable Diseases by a Grant from the Ministry of Health, Labor and Welfare of Japan (2007) Higher serum tenascin-C levels reflect the severity of heart failure, left ventricular dysfunction and remodeling in patients with dilated cardiomyopathy. Circ J 71:327–330PubMedCrossRef

12.

Siri A, Knäuper V, Veirana N, Caocci F, Murphy G, Zardi L (1995) Different susceptibility of small and large human tenascin-C isoforms to degradation by matrix metalloproteinases. J Biol Chem 270:8650–8654PubMedCrossRef

13.

Shah PK, Falk E, Badimon JJ, Fernandez-Ortiz A, Mailhac A, Villareal-Levy G, Fallon JT, Regnstrom J, Fuster V (1995) Human monocyte-derived macrophages induce collagen breakdown in fibrous caps of atherosclerotic plaques. Potential role of matrix-degrading metalloproteinases and implications for plaque rupture. Circulation 92:1565–1569PubMed

14.

Kaartinen M, van der Wal AC, van der Loos CM, Piek JJ, Koch KT, Becker AE, Kovanen PT (1998) Mast cell infiltration in acute coronary syndromes: implications for plaque rupture. J Am Coll Cardiol 32:606–612PubMedCrossRef

15.

Fuster V, Stein B, Ambrose JA, Badimon L, Badimon JJ, Chesebro JH (1990) Atherosclerotic plaque rupture and thrombosis. Evolving concepts. Circulation 82:II47–II59PubMed

16.

Kovanen PT, Kaartinen M, Paavonen T (1995) Infiltrates of activated mast cells at the site of coronary atheromatous erosion or rupture in myocardial infarction. Circulation 92:1084–1088PubMedCrossRef

17.

Udalova IA, Ruhmann M, Thomson SJ, Midwood KS (2011) Expression and immune function of tenascin-C. Crit Rev Immunol 31:115–145PubMedCrossRef

18.

Sakata K, Kawashiri MA, Ino H, Matsubara T, Uno Y, Yasuda T, Miwa K, Kanaya H, Yamagishi M (2012) Intravascular ultrasound appearance of scattered necrotic core as an index for deterioration of coronary flow during intervention in acute coronary syndrome. Heart Vessels 27:443–452PubMedCrossRef

19.

Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, Yamagata K, Tomino Y, Yokoyama H, Hishida A (2009) Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis 53:982–992PubMedCrossRef

20.

Kusama I, Hibi K, Kosuge M, Sumita S, Tsukahara K, Okuda J, Ebina T, Umemura S, Kimura K (2012) Intravascular ultrasound assessment of the association between spatial orientation of ruptured coronary plaques and remodeling morphology of culprit plaques in ST-elevation acute myocardial infarction. Heart Vessels 27:541–547PubMedCrossRef

21.

Kenji K, Hironori U, Hideya Y, Michinori I, Yasuhiko H, Nobuoki K (2004) Tenascin-C is associated with coronary plaque instability in patients with acute coronary syndromes. Circ J 68:198–203PubMedCrossRef

22.

Sato A, Aonuma K, Imanaka-Yoshida K, Yoshida T, Isobe M, Kawase D, Kinoshita N, Yazaki Y, Hiroe M (2006) Serum tenascin-C might be a novel predictor of left ventricular remodeling and prognosis after acute myocardial infarction. J Am Coll Cardiol 47:2319–2325PubMedCrossRef

23.

Sato M, Toyozaki T, Odaka K, Uehara T, Arano Y, Hasegawa H, Yoshida K, Imanaka-Yoshida K, Yoshida T, Hiroe M, Tadokoro H, Irie T, Tanada S, Komuro I (2002) Detection of experimental autoimmune myocarditis in rats by ¹¹¹In monoclonal antibody specific for tenascin-C. Circulation 106:1397–1402PubMedCrossRef

24.

Chiquet-Ehrismann R, Chiquet M (2003) Tenascins: regulation and putative functions during pathological stress. J Pathol 200:488–499PubMedCrossRef

25.

Falk E (1983) Plaque rupture with severe pre-existing stenosis precipitating coronary thrombosis. Characteristics of coronary atherosclerotic plaques underlying fatal occlusive thrombi. Br Heart J 50:127–134PubMedCentralPubMedCrossRef

26.

Cowan KN, Jones PL, Rabinovitch M (2000) Elastase and matrix metalloproteinase inhibitors induce regression, and tenascin-C antisense prevents progression, of vascular disease. J Clin Invest 105:21–34PubMedCentralPubMedCrossRef

27.

Ross R, Glomset JA (1976) The pathogenesis of atherosclerosis (first of two parts). N Engl J Med 295:369–377PubMedCrossRef

28.

Schaff M, Receveur N, Bourdon C, Wurtz V, Denis CV, Orend G, Gachet C, Lanza F, Mangin PH (2011) Novel function of tenascin-C, a matrix protein relevant to atherosclerosis, in platelet recruitment and activation under flow. Arterioscler Thromb Vasc Biol 31:117–124PubMedCrossRef

29.

Wang L, Wang W, Shah PK, Song L, Yang M, Sharifi BG (2012) Deletion of tenascin-C gene exacerbates atherosclerosis and induces intraplaque hemorrhage in Apo-E-deficient mice. Cardiovasc Pathol 21:398–413PubMedCentralPubMedCrossRef

Title: Serum tenascin-C level is associated with coronary plaque rupture in patients with acute coronary syndrome
Authors: Nobuo Sakamoto
Yasuto Hoshino
Tomofumi Misaka
Hiroyuki Mizukami
Satoshi Suzuki
Koichi Sugimoto
Takayoshi Yamaki
Hiroyuki Kunii
Kazuhiko Nakazato
Hitoshi Suzuki
Shu-ichi Saitoh
Yasuchika Takeishi
Publication date: 01-03-2014
Publisher: Springer Japan
Published in: Heart and Vessels / Issue 2/2014
Print ISSN: 0910-8327
Electronic ISSN: 1615-2573
DOI: https://doi.org/10.1007/s00380-013-0341-2

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Serum tenascin-C level is associated with coronary plaque rupture in patients with acute coronary syndrome

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2014

A unique stenosis in saphenous vein graft visualized by optical coherence tomography

Growth differentiation factor 15 can distinguish between hypertrophic cardiomyopathy and hypertensive hearts

Gender modulates the aging effects on different patterns of early repolarization

Elevation of urinary liver-type fatty acid-binding protein as predicting factor for occurrence of contrast-induced acute kidney injury and its reduction by hemodiafiltration with blood suction from right atrium

Increased risk of acute myocardial infarction after the Great East Japan Earthquake

Thrombus-related focal in-stent restenosis after everolimus-eluting stent implantation